NCT06545682View on ClinicalTrials.gov

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

August 3, 2027

Study Completion Date

August 3, 2029

Conditions
Myelodysplastic Syndrome(MDS)Acute Myelogenous Leukemia (AML)
Interventions
DRUG

Alpelisib + Pembrolizumab

Given by mouth (PO) Given by vein (IV)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER